New and emerging disease modifying therapies for multiple sclerosis

@article{Saidha2012NewAE,
  title={New and emerging disease modifying therapies for multiple sclerosis},
  author={Shiv Saidha and Christopher Eckstein and Peter A. Calabresi},
  journal={Annals of the New York Academy of Sciences},
  year={2012},
  volume={1247}
}
Several disease‐modifying drugs (DMDs) are currently approved for the treatment of multiple sclerosis (MS). Recently, there has been increased identification and development of potential new treatments that may modulate the MS disease process, including oral therapies. Many of the newly approved MS therapies, as well as those in ongoing clinical trials, have the advantage of improved efficacy and/or being oral and more convenient, as compared to conventional injectable first‐line MS therapies… 
Established and novel disease‐modifying treatments in multiple sclerosis
TLDR
For patients with MS who present with highly inflammatory and potentially aggressive disease, the benefit‐to‐risk ratio may support initiating therapy using a drug with greater potential efficacy despite greater risks (e.g. fingolimod or natalizumab if JC virus antibody‐negative).
Pegylated Interferons: A Nurses’ Review of a Novel Multiple Sclerosis Therapy
  • Anne Howley, M. Kremenchutzky
  • Medicine
    The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses
  • 2014
TLDR
Peginterferon beta-1a, a pegylated form of interferons, is currently in phase III clinical trials for relapsing MS and has the potential to improve patient compliance by reducing the number of injections while maintaining clinical efficacy.
Infection Risk in Patients on Multiple Sclerosis Therapeutics
TLDR
The impact of infections on relapse rates in patients with MS is addressed in a comprehensive fashion, including a review of available infection data from pivotal trials and postmarketing studies for the approved and experimental DMTs, including frequency, types and severity of infections.
Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.
TLDR
Comparative pharmacogenetic analysis may allow the identification of the discriminative genetic biomarkers, which may be more informative for an a priori DMT choice than those found in conventional pharmacogenetics studies.
Targeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE
TLDR
Data indicate that inhibition of complement may offer an effective therapeutic approach to treating both acute and chronic forms of demyelinating disease through blocking the alternative pathway or complement convertases.
Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis.
TLDR
Compared with placebo, clear reductions in ARR with disease-modifying therapies were accompanied by more uncertain changes in disability progression, and interferon-beta-1b 250mcg ranked among the most efficacious treatments for disability progression confirmed after six months and among the least efficacious when the outcome was confirmed after three months.
OCT in Relapsing–Remitting Multiple Sclerosis (RRMS)
TLDR
The salient features of optic nerve and retinal involvement in RRMS are described, what OCT is and what OCT studies have thus far revealed, and the potential role of OCT as an outcome in RR MS clinical trials are discussed.
Influence of Peripheral inflammation on the progression of multiple sclerosis: Evidence from the clinic and experimental animal models
TLDR
The existing data on the inflammatory component of MS is reviewed, with special attention on the effect of peripheral infections in the etiology and progression of MS and its effect on the relapsing and remitting episodes and the effects of peripheral inflammatory events in MS experimental animal models are analyzed.
An emerging potential of metabolomics in multiple sclerosis: a comprehensive overview
TLDR
The metabolomics studies suggest that metabolic profiling of MS patient samples may uncover biomarkers that will advance the understanding of disease pathogenesis and progression, reduce delays and mistakes in diagnosis, monitor the course of disease, and detect better drug targets, all of which will improve early therapeutic interventions and improve evaluation of response to these treatments.
Role of Regulatory T Cells in Pathogenesis and Biological Therapy of Multiple Sclerosis
  • M. Buc
  • Medicine
    Mediators of inflammation
  • 2013
TLDR
Known mechanisms of action, efficacy, and side-effects of contemporary and emerging MS immunotherapeutical agents on Treg cells and other cells of the immune system involved in the immunopathogenesis of the disease are described.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 188 REFERENCES
Immune mechanisms of new therapeutic strategies in MS: teriflunomide.
TLDR
Due to its favorable safety profile and its efficacy in rheumatoid arthritis where the aberrant immune response is in various aspects similar to the autoimmune reaction in MS patients, teriflunomide is a promising treatment option for MS patients.
Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide
Linomide (quinoline-3-carboxamide) is a synthetic immunomodulator that increases the natural killer cell activity. We previously demonstrated that linomide effectively inhibited the clinical and
Laquinimod, a new oral autoimmune modulator for the treatment of relapsing-remitting multiple sclerosis.
  • A. Tselis
  • Medicine
    Current opinion in investigational drugs
  • 2010
TLDR
Two phase III clinical trials are ongoing and, if successful, will lead to the approval of the first oral immunomodulatory drug for suppressing multiple sclerosis disease activity.
Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta.
  • G. Comi
  • Medicine
    Clinical therapeutics
  • 2009
TLDR
The evidence that axonal damage begins in the early stages of MS, before symptoms are evident, provides a rationale for early intervention with immunomodulatory agents.
Treatment of multiple sclerosis with anti-CD20 antibodies.
TLDR
The focus will be to review results that have emerged over the last few years from clinical trials of different anti-CD20 mAbs in patients with MS, and to consider the biological basis underlying the apparent therapeutic efficacy of B cell depletion in MS.
Biomarkers and surrogate outcomes in neurodegenerative disease: Lessons from multiple sclerosis
TLDR
For treatment trials of new agents aimed at preventing disability, measures of neuroaxonal damage should be acquired, especially atrophy, which occurs at all stages of MS and can be quantified in a sensitive and reproducible manner.
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
TLDR
Interferon beta‐ la had a significant beneficial impact in relapsing multiple sclerosis patients by reducing the accumulation of permanent physical disability, exacerbation frequency, and disease activity measured by gadolinium‐enhanced lesions on brain magnetic resonance images.
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
TLDR
Both doses of oral fingolimod improved the relapse rate, the risk of disability progression, and end points on MRI and were superior to placebo with regard to MRI-related measures.
Oral fingolimod (FTY720) in multiple sclerosis
TLDR
Once-daily oral treatment with FTY720, 1.25 or 5.0 mg, for up to 2 years, was well tolerated and was associated with low relapse rates and lesion activity.
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
TLDR
This trial showed the superior efficacy of oral fingolimod with respect to relapse rates and MRI outcomes in patients with multiple sclerosis, as compared with intramuscular interferon beta-1a.
...
1
2
3
4
5
...